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Abstract
Adequate pain relief in patients with far advanced cancer sometimes requires intrathecal (IT) administration of a com bination o f  
opioids and local anesthetics. Tumor progression as well as the IT administration of local anesthetics can lead to neurologic dysfunction  
during treatment. Five patients showed symptoms o f compression of the cauda equina or spinal cord shortly after the start of com bined  
IT administration o f morphine and bupivacaine in a dosage usually not associated with neurologic symptoms. Unexpectedly, neurologic 
evaluation suggested compression o f the cauda equina and spinal cord, which was confirmed radiographically. Manifestation o f  new  
neurologic symptoms during low dose bupivacaine infusion intrathecally might therefore be an early indicator of space-occupying  
processes within the spinal canal in cancer patients.
K eyw ords:  Intrathecal morphine/bupivacaine; Metastatic cancer; Neurologic dysfunction; Spinal cord and cauda equina compression
1. Introduction
In about 15% of cancer patients, neurologic symptoms 
can be present during the course of the disease (Posner, 
1995). Compression o f the spinal cord or cauda equina 
manifests clinically in about 5% of cancer patients (Gilbert 
et a l, 1978; Schiff et al., 1995) and is usually accompanied 
by pain complaints in the back, with or without radiation 
into an extremity. Frequently, sensory disturbances, motor 
weakness ultimately leading to paralysis, and problems 
with fecal and urinary continence can follow if left 
untreated (Portenoy, 1987).
In some of these patients, pain relief can either remain 
inadequate despite the administration of various analgesics 
including opioids or can be accompanied by intolerable 
side-effects. Spinal (i.e., epidural, intrathecal (IT)) admin­
istration o f morphine may then be considered (Krames et 
a l, 1985; Onofrio and Yaksh, 1990) although neurogenic 
pain components do not always respond favourably (Arnér 
and Arnér, 1985; Max et al., 1985). Recently a combina-
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tion of intrathecally administered morphine and bupiva­
caine (an amide-type local anesthetic) was proposed as a 
step forward toward the solution of these intractable pain 
problems (van Dongen et al., 1993; Sjoberg et a l ,  1994). 
Usually a wide dosage range of IT bupivacaine is tolerated 
without severe side-effects below a bupivacaine dosage of 
45 mg day*1 (Sjoberg et alM 1994), but individual titration 
remains mandatory to prevent neurologic dysfunction. We 
report five cancer patients who developed unexpected, 
severe, neurologic disturbances during continuous, low- 
dose, IT morphine/bupivacaine infusions. The clinical 
signs, differential diagnosis and management are 
described.
2. Case histories
2.1. Patient no. 1
A 63-year-old man suffered from increasing back pain, 
radiating into the anterior side of both legs despite high 
oral morphine (480 mg day'1) intake. The pain was related 
to widespread bone métastasés of a prostatic carcinoma. 
Diffuse vertebral métastasés were shown previously on
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scan. Neurologic function was norm a l  À kirnbar IT 
?r was inserted. As an initial IT infusion of  morphine 
-).6 ni g day '1) did not resu H in adequate pain relief, bupi-
"l) was added to the infusion. Pain5 mg dayvacaine t
elief  improved but was accompanied by complete motor 
and sensory block of  the left leg below the 12 dermatome 
and urinary incontinence, CT scanning performed there- 
af  te r w as s u spicious for epidural com press i o n of t h e spin al 
cord and cauda equina at the level of  T h l2 -L 3  (Fig, 1), 
Systemic corticosteroids and radiotherapy resulted in 
relief o f  the pain and partial restoration of motor function 
thereafter, The IT infusion was continued until death, due 
to respiratory insufficiency, two weeks later, without pro­
gression of  motor weakness in the legs.
2.2. Pai lent no. 2
A 45-year-old woman presented with vertebral metas- 
tases, nine years after primary resection and radiotherapy 
o f  an adenocystic carcinoma of the parotid gland. One year 
before the start of the IT infusion for pain relief, radio­
therapy to the vertebral column was started for complete 
destruction of the body of the LI vertebra, At that time, a 
pathological fracture of LI with compression of the cauda 
equina and the spina! cord with weakness of both legs was
Following radiotherapy and corticosteroids, an initial 
deterioration in neurologic function, with progressive 
motor weakness of the legs and problems with micturition, 
was present but these symptoms gradually disappeared 
with minimal radiation of pain into the right leg in the
weeks thereafter. On readmission one year later, a ’belt- 
like’ pain in the lower back and legs had returned despite 
h id)  doses of  oral morphine,  dex trom oram ide ,  earbaina- 
zepine and tricyclic antidepressants.  Slight paraesthesiae 
were present in the right leg without signs of m otor  w eak­
ness. A lumbar IT catheter was inserted and as morphine 
only (7.2 mg day-1) did not result in adequate pain relief, a 
mixture of  morphine/bupivacaine  was infused continu­
ously thereafter. At a dosage of 7.2 mg morphine and 
21.6 mg bupivacaine per day, the patient experienced 
severe muscular weakness in both legs and inability to 
walk alone. Diminishing the daily IT bupivacaine to 7.2 
mg, adding clonidine (150 ¡xg d a y '1) and increasing the 
morphine (14.4 mg d ay“1), resulted in improved motor 
performance and adequate pain relief. During palliative 
treatment at home, paraplegia probably due to ongoing 
spinal cord compression presented before death.
2.3. Patient no. 3
A 67-year-old wom an presented with severe low back 
pain radiating to the thoracic region as well as the back and 
sides of  both legs despite oral morphine  (260 rng d a y '1). 
Global hypesthesia was present from the groin dow n to the 
feet in both legs. Five years previously, a Grawitz  tumor 
with local-regional spread was resected. A year  before 
start of  IT treatment, multiple pathological  fractures in 
both humeri and left femur developed,  all treated pallia- 
tively by osteosynthesis and radiotherapy. Because of  per­
sistent, severe back pain, a lum bar  IT catheter was 
inserted, delivering a combinat ion  o f  morphine and bupi­
vacaine and resulting in significant decrease in pain. Fol­
lowing a gradual increase o f  the infusion rate during the 
three days thereafter, motor blockade in both legs and loss 
of bladder control developed at a bupivacaine dosage of  36 
mg day“1. The bupivacaine dosage was reduced to 15 mg 
d a y '1 while morphine remained at around 15 rng day-1. 
Epidural compression or lumbar p lexopathy was sus­
pected, On MRI scanning (see Fig. 2) a large mass could 
be seen eroding the posterior side o f  the body o f  L4 with 
extension into the epidural space, complete ly  occluding 
the spinal subarachnoid space.
Oral dexamethasone 16 mg day"1 was started and despite 
a slight increase of  the bupivacaine to 24 mg day"1 neuro­
logical improvement with restoration o f  assisted walking 
could be attained. T he  patient died at home free of  pain 
with slight motor weakness  at day 42 without further 
increase in IT infusion rate.
2.4. Patient no. 4
Fig. !. CT-scan  (transverse plane) at the level of Th 12 o f  patient I 
show ing  pathologic changes in the posterolateral border o f  the corpus 
o f  the vertebra, lining the spinal canal (asterisk). Disappearance o f  the 
epidural fat is highly suggestive for epidural  metastasis here. The white 
dot  (arrow) in the anterior part of the spinal canal is the IT catheter.
A 45-year-old , man underwent  s igmoid  resection 
because o f  adenocarc inom a one year before the start of 
IT treatment. As a child, he contracted poliomyelit is  and 
meningitis. However,  neither had any deleterious long­
term effect on motor function in his legs. Subsequen t  che-
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at home, free of pain, without additional analgesics, four 
weeks later.
Fig. 2. M R I-sc a n  o f  pat ient  HI (sagit tal  p lan e )  at th e  l u m b a r  area .  A. la rge  
mass in con tac t  with  the L IV ver tebra ,  c o m p le t e ly  tills the sp ina!  cana l  
at this level.
motherapy (5 FU, methotrexate) to treat liver metastases 
during the year following the operation, did not result in 
remission of the disease. Unbearable, lancinating pain, 
attacks radiating from the groin into hits left leg and foot 
were accompanied by sensory loss and paraesthesiae in a 
skin area in the left lumbosacral region. Clinically, a lum­
bosacral plexopathy due to tumor invasion or compression 
was suspected. Other neurologic signs were limited to 
slight difficulty with micturition without signs of motor 
impairment. A plain X-ray of the lumbar vertebral column 
one month previously did not show abnormalities, Further 
radiologic examination was not performed. Slow release 
oral morphine (MS continR; 30 mg bd), amitriptyline and 
carbamezapine, did not result in adequate pain relief and 
severe neuropathic pain attacks persisted in combination 
with bothersome sedative effects. A lumbar subcuta- 
neously tunnelled IT catheter was inserted. A solution con­
taining morphine MCI 0.5 mg.ml“1 and bupivacaine 3 
m g .m l1 was started and gradually increased to a rate of 
0.3 ml.hr"1 (3.6 mg morphine and 21.6 mg bupivacaine per 
day respectively). Progressive neurological dysfunction
with proximal and distal motor weakness in the left leg 
and global hypesthesia of the dermatomes L5 to S5 with 
inability to void developed at this dosage within 48 hours, 
with adequate analgesia. Although bupivacaine-induced 
side-effects were suspected, cauda equina compression 
due to epidural tumor spread was also considered. On 
MR] scanning, a large tumor mass eroding the sacral 
area from the left and extending to the pelvic cavity was 
observed.
The sacral canal was compressed due to epidural tumor 
growth. Palliative radiotherapy and oral dexamethasone 
were started. The IT infusion was not diminished due to 
the patient’s severe anxiety that the pain would return. The 
paralysis of the left leg did not subside. The patient was 
discharged with continuation of the IT treatment and died
2.5. Palient no. 5
A 67-year-old man was treated by radiotherapy to the 
right lung and mediastinum for squamous cell bronchial 
carcinoma three years before admission, Due to progrès-
s ive tumor growth with invasion of the thoracic vertebrae 
(Th 11-12) ancl spinal canal with imminent spinal cord 
compression, palliative radiotherapy was started. As con­
ventional pain relief was inadequate and accompanied by 
severe constipation, an IT catheter was inserted at a lumbar 
(L2-L3) interspace initially delivering morphine 4 mg 
day '1. As pain persisted, bupivacaine was added IT at a 
dosage of 2.5 mg day '1. Despite adequate pain relief, 10 
days after catheter insertion, paraplegia developed with 
suspicion of ongoing compression of the cord. However, 
cessation of the IT bupivacaine and increase of morphine 
IT (6 mg day"1) resulted in complete restoration of  motor 
function of the legs with adequate pain relief thereafter. No 
neurological symptoms recurred before death.
3. D iscussion
In progressive cancer syndromes, severe back pain in 
combination with motor and sensory disturbances in a leg 
and problems with micturition can be caused by compres­
sion o f  the spinal cord or cauda equina as well as by tumor 
infiltration of the nerve roots or plexus (Jaeckle et al., 
1985; Portenoy et al., 1987). In these situations, increasing 
the dosage of  analgesics, including morphine, is usually 
considered first. Also co-administration of anticonvulsant, 
antidepressant drugs or corticosteroids can be beneficial 
(Portenoy, 1991; Cherry and Portenoy, 1993).
Even when morphine is administered intrathecally, pain 
relief can still be insufficient especially when neurogenic 
pain components are present. Co-administration of bupi­
vacaine IT has been advocated to improve pain relief sub­
stantially in these situations and we used this technique in 
our patients (Sjoberg et al., 1991). Morphine IT does not 
give rise to motor or sensory impairment and IT bupiva­
caine below a dosage of 45 rng day“1, by continuous infu­
sion has been reported not to produce neurological side- 
effects either (Sjoberg et al., 1994). We did not observe 
neurological deficits below a bupivacaine dosage of 30 mg 
day '1 IT in a study of  patients with an undisturbed neuro­
logic history (van Dongeri et al., 1993), and thus we did not 
expect to be confronted with such, profound neurologic 
changes with these low IT bupivacaine dosages.
Severe pain complaints usually precede the clinical 
manifestation of compression of the spinal cord or plexus 
invasion during a variable period (Gilbert et al., 1978) in 
which the patient is usually just able to compensate for the 
impaired neurological function. Moreover, estimation of  
normal activity is severely impeded by the pain com­
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plaints. Subsequent effective pain treatment with a combi­
nation o f IT morphine/bupivacainc might lead to ‘unmask­
ing' of the subtle neurological deficits, which would 
otherwise stay undetected for a further period. One 
might argue therefore that the neurological deficits found 
were merely the result of ongoing compression. On the 
other hand, in all patients, neurologic symptoms were 
related to the start of IT bupivacaine infusion or improved 
following the diminution of the IT dose. This is highly 
suggestive of a bupivacaine-related effect in these patients. 
Early diagnosis and adequate treatment of compression is 
important as the outcome is closely related to the duration 
of the compression and the neurologic deficits at the 
moment o f diagnosis (Portenoy et al., 1987; Schiff et al., 
1995).
As a differential diagnosis for neurological deficits in 
cancer patients with pain and dysfunction in a leg, lumbo­
sacral plexopathy should be considered (Jaeckle et al., 
1985). Finally, infectious complications (meningitis, 
abscess formation), epidural hematoma formation both 
due to the presence of the IT catheter and late effects of 
radiation myelopathy may give rise to similar neurologic 
dysfunction (Wara and Larson, 1991; Table 1).
In these patients, however, these causes were excluded 
due to the absence of related clinical manifestations and 
the partial reversibility of the symptoms following the 
reduction of the bupivacaine administered.
It is unclear what is the exact mechanism of this 
increased ’susceptibility’ for bupivacaine IT in these 
patients. We assume that the neurologic disturbances 
were caused primarily by the subclinical compression of 
the spinal cord and cauda equina, which can be easily 
overlooked during initial patient evaluation. Extreme neu­
rogenic pain complaints can hinder ambulation and routine 
neurologic testing, whereas the unselective sensory and 
motor blocking effects of bupivacaine interfere with this 
compromised neurologic status.
A  wide range of IT bupivacaine dosages seems to be 
tolerated (Sjoberg et al., 1994) suggesting differences in 
sensitivity, probably influenced also by pharmacological 
factors. Both pharmacokinetic (e.g., altered distribution of 
the drug in the CSF with locally increased concentrations 
due to obstruction of normal CSF flow; proximity of the 
catheter tip to a spinal root) as well as pharmacodynamic 
factors (e.g., increased toxicity of local anesthetics in the 
presence o f neurologic dysfunction, changes in CSF com-
Table 1
Differentia] diagnosis of neurologic symptoms in cancer patients 
Due to primary tumor/metastasis
Due to endocrine disturbances (e.g., ADH, glucose, Ca, electrolytes)
Cerebral and spinal vascular disease
Primary treatment related (chemotherapy, radiotherapy)
CNS infections 
Paraneoplastic syndromes
Table 2
Dosages of bupivacaine IT and clinical signs during neurological deficit
Patient Bupivacaine3 Radiography
1 15 compression Thl2-L2
2 22 compression LI
3 36 compression L4
4 22 compression cauda
5 2.5 compression Th 11-12
aDosage of bupivacaine in mg day'1 by continuos IT infusion at moment 
of neurologic deficit.
position or pH), may be of importance (Jones and Healy, 
1980).
In our view, the most striking observation in the patients 
reported here was that neurologic deterioration took place 
during a low dose IT administration o f bupivacaine while 
other symptoms suggestive o f spinal cord or cauda equina 
compression were clinically absent or unremarkable 
(Table 2).
The continuous IT co-administration of bupivacaine 
with morphine, necessitated by the pain syndrome, more 
or less ‘revealed1 the presence o f compression. When this 
occurs in patients with previous relatively undisturbed 
neurology, one should consider this as additional diagnos­
tic information. We recommend that besides the pain his­
tory and diagnosis o f the pain syndrome (Arnér and Arnér, 
1985), a neurological examination combined with radio- 
graphic evaluation of the vertebral column including CT or 
MRI is considered before the start of IT treatment. This 
may be even more important when the use o f IT local 
anesthetics seems to be inevitable.
Specific attention should be given to those patients sus­
pected of having compression o f the spinal cord and cauda 
equina, as conventional radiologic examination may show 
no abnormalities and MRI scanning is not always avail­
able. Early diagnosis o f the likely cause o f neurological 
deterioration after initiation o f IT morphine/bupivacaine 
administration is important, not only when there are still 
palliative treatment modalities available but also because 
neurological deterioration may have devastating func­
tional and emotional consequences.
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